Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04313881
Title Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Gilead Sciences
Indications

myelodysplastic syndrome

Therapies

Azacitidine

Azacitidine + Hu5F9-G4

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.